Glenmark and MeyerZall Laboratories to offers topical dermatology products in South Africa

25 Oct 2007

1
Glenmark Pharmaceuticals South Africa today announced the expansion of its topical dermatology portfolio with the signing a 10-year marketing and distribution rights agreement with MeyerZall Laboratories.

Therapeutic areas covered by this distribution agreement include psoriasis, fungal infections of the skin and inflammation with the following products now falling into the Glenmark portfolio; Linotar Gel 1, Covarex and Athru-Derm, all with unique patented delivery systems which are available for distribution through the South African public health distribution network.

"With the addition of these products to Glenmark''s portfolio, we are now able to offer one of the widest topical dermatology baskets in the South African market,: said A S Mohanty, director, formulations, Glenmark Pharmaceuticals Ltd. "This will significantly add to our existing range of Synalar, Synalar-C, Synalar-N and Naseptin, and create a significant niche in the area of dermatology for Glenmark in South Africa."

In December 2005, Glenmark Pharmaceuticals Ltd acquired Bouwer Bartlett Pty Ltd, a South African sales and marketing company, through Glenmark Pharmaceuticals S,A, its wholly owned Swiss subsidiary.

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more